.
MergerLinks Header Logo

Announced

HDL Therapeutics to go public via a SPAC merger with Swiftmerge Acquisition in a $480m deal.

Financials

Edit Data
Transaction Value£378m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Biotechnology

De-SPAC

United States

Reverse Takeover

biotech

Cross Border

Single Bidder

Private

Acquisition

Majority

Pending

Friendly

Synopsis

Edit

HDL Therapeutics, a privately held commercial stage biotech company, agreed to go public via a SPAC merger with Swiftmerge Acquisition, a special purpose acquisition company, in a $480m deal. “We are thrilled to partner with Swiftmerge and hope to bring our groundbreaking treatment to appropriate patients around the world. Our treatment has the potential to benefit countless lives with the hope of one day eradicating coronary atherosclerosis as we know it,” Michael Matin, HDL Therapeutics Chairman and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US